Biology:SPH3127

From HandWiki
Short description: Chemical compound
SPH3127
SPH3127.svg
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H32N6O4
Molar mass444.536 g·mol−1
3D model (JSmol)

SPH3127 is a small-molecule renin inhibitor developed by Shanghai Pharmaceuticals for hypertension and kidney disease. It is believed to be more potent than aliskiren.[1][2][3]

References

  1. Iijima, Daisuke; Sugama, Hiroshi; Takahashi, Yoichi; Hirai, Miki; Togashi, Yuko; Xie, Jianshu; Shen, Jingkang; Ke, Ying et al. (25 August 2022). "Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor". Journal of Medicinal Chemistry 65 (16): 10882–10897. doi:10.1021/acs.jmedchem.2c00834. PMID 35939295. 
  2. Zhang, Leduo; Mao, Yu; Gao, Zhiwei; Chen, Xiaoyan; Li, Xin; Liu, Yanjun; Xia, Guangxin (February 2020). "The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor". European Journal of Drug Metabolism and Pharmacokinetics 45 (1): 15–26. doi:10.1007/s13318-019-00573-9. PMID 31494843. 
  3. Jing, Shan; Xu, Ranchi; Yang, Kexu; Liu, Wenfang; Zhang, Leduo; Ke, Ying; Xia, Guangxin; Lin, Yang (April 2021). "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial". Clinical Therapeutics 43 (4): 735.e1–735.e14. doi:10.1016/j.clinthera.2021.01.025. PMID 33653620.